Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 1;10:8858. doi: 10.1038/s41598-020-65649-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Inhibiting miR-149-5p attenuates propofol effects. (A) Trastuzumab-resistant SKBR3 cells were treated with increasing doses of trastuzumab as indicated on X-axis in the presence of either DMSO vehicle or 5 μg/ml propofol for 96 h. Additionally, Trastuzumab-resistant cells transfected with anti-miR-149-5p oligos (Anti-miR) were also evaluated. Cell viability was calculated by CCK8 assay. The number of viable cells in 0 μg/ml trastuzumab treated vehicle group were regarded as 100% and the ‘relative’ percentage in other groups was calculated. Trastuzumab-resistant (Tr-R) (B) SKBR3 or (C) HTB-20 cells were treated with either DMSO vehicle or 5 μg/ml propofol for 96 h. Additionally, Trastuzumab-resistant cells transfected with anti-miR-149-5p oligos (Anti-miR) were also evaluated. Cell culture supernatant was collected and ELISA was performed to quantitate levels of IL-6. ^#p < 0.01, compared to vehicle and ^$p < 0.01, compared to propofol alone.